Free Trial

89bio, Inc. (NASDAQ:ETNB) Short Interest Update

89bio logo with Medical background

89bio, Inc. (NASDAQ:ETNB - Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 6,450,000 shares, a drop of 7.1% from the September 15th total of 6,940,000 shares. Based on an average daily trading volume, of 616,600 shares, the days-to-cover ratio is currently 10.5 days.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Capstone Investment Advisors LLC purchased a new position in 89bio during the 1st quarter valued at about $1,208,000. Candriam S.C.A. boosted its holdings in shares of 89bio by 173.6% during the second quarter. Candriam S.C.A. now owns 848,079 shares of the company's stock worth $6,793,000 after purchasing an additional 538,079 shares during the period. Westfield Capital Management Co. LP grew its position in 89bio by 22.9% during the first quarter. Westfield Capital Management Co. LP now owns 2,164,147 shares of the company's stock valued at $25,191,000 after purchasing an additional 402,999 shares in the last quarter. Vanguard Group Inc. increased its stake in 89bio by 9.6% in the 1st quarter. Vanguard Group Inc. now owns 4,722,971 shares of the company's stock valued at $54,975,000 after buying an additional 415,386 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in 89bio in the 2nd quarter worth approximately $2,238,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Raymond James boosted their price target on shares of 89bio from $50.00 to $53.00 and gave the stock a "strong-buy" rating in a research report on Tuesday, August 6th. HC Wainwright reissued a "buy" rating and set a $29.00 target price on shares of 89bio in a research note on Tuesday, August 6th. Royal Bank of Canada reduced their target price on shares of 89bio from $13.00 to $12.00 and set a "sector perform" rating for the company in a report on Tuesday, August 6th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $29.00 price target on shares of 89bio in a report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $31.00.

Get Our Latest Stock Report on ETNB

89bio Trading Down 4.6 %

Shares of 89bio stock traded down $0.40 during trading on Thursday, hitting $8.21. The stock had a trading volume of 521,147 shares, compared to its average volume of 962,525. 89bio has a 1 year low of $6.57 and a 1 year high of $16.63. The stock has a 50 day simple moving average of $8.15 and a 200 day simple moving average of $8.56. The company has a quick ratio of 13.92, a current ratio of 13.92 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $807.73 million, a PE ratio of -4.08 and a beta of 1.09.

89bio (NASDAQ:ETNB - Get Free Report) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.08. During the same quarter in the previous year, the firm earned ($0.52) EPS. On average, research analysts expect that 89bio will post -2.32 EPS for the current fiscal year.

About 89bio

(Get Free Report)

89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia.

Featured Articles

Should you invest $1,000 in 89bio right now?

Before you consider 89bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 89bio wasn't on the list.

While 89bio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines